Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2007

Content (17 Articles)

Preclinical Study

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin

Wieslawa H. Dragowska, Maïté Verreault, Donald T. T. Yapp, Corinna Warburton, Lincoln Edwards, Euan C. Ramsay, Lynsey A. Huxham, Andrew I. Minchinton, Karen Gelmon, Marcel B. Bally

Preclinical Study

The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells

Bernd C. Schmid, Günther A. Rezniczek, Gerhild Fabjani, Toshiyuki Yoneda, Sepp Leodolter, Robert Zeillinger

Preclinical Study

Endothelial progenitor cells in breast cancer patients

Christiane Richter-Ehrenstein, Jörn Rentzsch, Sanyukta Runkel, Achim Schneider, Gilbert Schönfelder

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer

Sofia Kouidou, Andigoni Malousi, Anastasios Kyventidis, Aikaterini Fragou, Nicos Maglaveras

Preclinical Study

On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer

Martin Smollich, Martin Götte, George W. Yip, Eng-Siang Yong, Christian Kersting, Jeanett Fischgräbe, Isabel Radke, Ludwig Kiesel, Pia Wülfing

Preclinical Study

VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

Amanda K. Laust, Brandon W. Sur, Kehui Wang, Bolyn Hubby, Jonathan F. Smith, Edward L. Nelson

Clinical Trial

CYP1B1 and predisposition to breast cancer in Poland

Joanna Matyjasik, Cezary Cybulski, Bartlomiej Masojć, Anna Jakubowska, Pablo Serrano-Fernandez, Bohdan Górski, Tadeusz Dębniak, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Elzbieta Złowocka, Steven Alexander Narod, Rodney Scott, Jan Lubinski

Clinical Trial

A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women

Robert Mansel, Amit Goyal, Elisabeth Le Nestour, Valérie Masini-Etévé, Katharine O’Connell

Clinical Trial

Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis?

Elisabeth Mueller-Holzner, Thomas Frede, Martin Daniaux, Michael Ban, Susanne Taucher, Alois Schneitter, Alain G. Zeimet, Christian Marth

Clinical Trial

Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer

Chonghua Wan, Dongmei Zhang, Zheng Yang, Xin Tu, Wan Tang, Changyong Feng, Hongyue Wang, Xueliang Tang

Epidemiology

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival

Sylvie Bérubé, Louise Provencher, Jean Robert, Simon Jacob, Nicole Hébert-Croteau, Julie Lemieux, Thierry Duchesne, Jacques Brisson

Epidemiology

Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement

Kyoung-Mu Lee, Ji-Yeob Choi, Jong Eun Lee, Dong-Young Noh, Sei-Hyun Ahn, Wonshik Han, Keun-Young Yoo, Richard B. Hayes, Daehee Kang

Epidemiology

Risk of second non-hematological malignancies among 376,825 breast cancer survivors

Linda Morris Brown, Bingshu E. Chen, Ruth M. Pfeiffer, Catherine Schairer, Per Hall, Hans Storm, Eero Pukkala, Frøydis Langmark, Magnus Kaijser, Michael Andersson, Heikki Joensuu, Sophie D. Fosså, Lois B. Travis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine